mHealth Spot

Aily Labs lists on Google Cloud Marketplace, targeting pharma and biotech

Most pharmaceutical companies sit on enormous amounts of data that never reaches the people making decisions. Aily Labs, the Munich and New York-based decision intelligence company, is now listed on Google Cloud Marketplace, a move designed to close exactly that gap, faster and with less friction than a typical enterprise software rollout.

What the partnership actually means

Enterprises already running on Google Cloud can procure Aily’s platform through their existing cloud contracts, with spend counting toward committed cloud agreements. Once deployed, Aily’s AI agents sit inside the company’s Agent Gallery within Gemini Enterprise. No separate compliance review. No new vendor onboarding. That’s a meaningful reduction in the procurement drag that typically slows AI adoption in regulated industries.

What Aily’s platform does

The platform connects fragmented data systems and produces specific recommendations for decision-makers through a single interface called the Super Agent, which coordinates specialized AI agents across multiple functions. Pharmaceutical companies are the primary target, with use cases across:

Why it matters for life sciences

Data fragmentation is a chronic problem in pharma. Research, manufacturing, and commercial teams often operate from separate systems that don’t talk to each other. Aily’s pitch is that its platform connects those silos and surfaces decisions, not just dashboards. The Google Cloud integration adds infrastructure credibility and distribution reach that a standalone vendor would struggle to match.

The bigger picture

Aily Labs has raised over $101 million to date, including an $80 million round last November led by FPV Ventures, with J.P. Morgan and Insight Partners among the backers. The Google Cloud listing is a distribution bet, not a technology announcement. But for health system operators and pharma IT leaders already committed to Google Cloud infrastructure, it removes a real barrier to trialing the platform.

Exit mobile version